Seoul Pharma Co. Ltd (018680) - Total Liabilities

Latest as of September 2025: ₩32.70 Billion KRW ≈ $22.16 Million USD

Based on the latest financial reports, Seoul Pharma Co. Ltd (018680) has total liabilities worth ₩32.70 Billion KRW (≈ $22.16 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Seoul Pharma Co. Ltd equity growth rate to track the company's year-over-year net asset growth rate.

Seoul Pharma Co. Ltd - Total Liabilities Trend (2012–2024)

This chart illustrates how Seoul Pharma Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. See Seoul Pharma Co. Ltd free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.

Seoul Pharma Co. Ltd Competitors by Total Liabilities

The table below lists competitors of Seoul Pharma Co. Ltd ranked by their total liabilities.

Company Country Total Liabilities
Shinpoong Pharmaceutical Co Ltd
KO:019175
Korea ₩79.62 Billion
LL Lucky Games publ AB
ST:LADYLU
Sweden Skr35.38 Million
Giga Media Ltd
NASDAQ:GIGM
USA $3.06 Million
KB SPAC 5
KQ:208350
Korea ₩19.20 Billion
Korea Plasma Technology U Co.Ltd
KQ:054410
Korea ₩39.75 Billion
Minox International Group Berhad
KLSE:0288
Malaysia RM23.48 Million
Garovaglio y Zorraquin S.A.
BA:GARO
Argentina AR$41.64 Billion
Labo Print SA
WAR:LAB
Poland zł68.75 Million

Liability Composition Analysis (2012–2024)

This chart breaks down Seoul Pharma Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 018680 stock market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.17 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.79 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.44 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Seoul Pharma Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Seoul Pharma Co. Ltd (2012–2024)

The table below shows the annual total liabilities of Seoul Pharma Co. Ltd from 2012 to 2024.

Year Total Liabilities Change
2024-12-31 ₩31.45 Billion
≈ $21.31 Million
+27.11%
2023-12-31 ₩24.74 Billion
≈ $16.77 Million
-8.39%
2022-12-31 ₩27.01 Billion
≈ $18.30 Million
-37.62%
2021-12-31 ₩43.29 Billion
≈ $29.34 Million
+19.48%
2020-12-31 ₩36.23 Billion
≈ $24.56 Million
-14.62%
2019-12-31 ₩42.44 Billion
≈ $28.76 Million
+5.43%
2018-12-31 ₩40.25 Billion
≈ $27.28 Million
+21.70%
2017-12-31 ₩33.08 Billion
≈ $22.42 Million
-34.47%
2016-12-31 ₩50.47 Billion
≈ $34.20 Million
+2.70%
2015-12-31 ₩49.15 Billion
≈ $33.31 Million
+2.65%
2014-12-31 ₩47.88 Billion
≈ $32.45 Million
+22.23%
2013-12-31 ₩39.17 Billion
≈ $26.55 Million
+10.99%
2012-12-31 ₩35.29 Billion
≈ $23.92 Million
--

About Seoul Pharma Co. Ltd

KQ:018680 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$15.37 Million
₩22.68 Billion KRW
Market Cap Rank
#25887 Global
#1932 in Korea
Share Price
₩1945.00
Change (1 day)
-2.31%
52-Week Range
₩1945.00 - ₩3385.00
All Time High
₩17976.69
About

Seoul Pharma Co., Ltd manufactures and sells pharmaceutical products in South Korea and internationally. The company offers orally disintegrating film products for therapeutic areas, including urology, neurology, nutrition, endocrinology, and OB/GY. Its products include VULTEUM and VULTIS for erectile dysfunction; ARTPEZIL for Alzheimer' disease; OBCARE to treat overactive bladder with symptoms o… Read more